Medicines appraisal cards

Medicines appraisal cards have been developed for the Guidelines in Practice audience to announce new recommendations from the National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC), and the All Wales Medicines Strategy Group (AWMSG). Items may contain pharmaceutical promotional information.

Evenity index image

Romosozumab▼ (Evenity®) 105mg solution for injection in prefilled pen SMC2280

Commissioned by UCB Pharma Ltd

The production of this Guidelines card has been commissioned by UCB Pharma Ltd. 
Amgen and UCB Pharma Ltd are co-developing Evenity®.
View prescribing information and adverse event reporting
UK-P-RM-OP-2000095 December 2020

20210203 Beovu TA card front cover image

NICE Technology Appraisal 672: ▼Brolucizumab for treating wet age-related macular degeneration

Commissioned by Novartis Pharmaceuticals UK Ltd

The printing of this Guidelines summary card has been commissioned by Novartis Pharmaceuticals UK Ltd. Information intended for UK healthcare professionals only.
Click here for Prescribing information and Adverse Event Reporting.

MLR ID 103903
Date of preparation: February 2021

20201022 SMC card hosting page image new PI V1

▼Brolucizumab (Beovu®) 120mg/mL solution for injection in pre-filled syringe SMC2272

Commissioned by Novartis Pharmaceuticals UK Ltd

The production of this Guidelines card has been commissioned by Novartis Pharmaceuticals UK Ltd. Information intended for healthcare professionals only.
Click here for Prescribing information and Adverse Event Reporting.

BEO20-C089b (1)
Date of preparation: October 2020